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ABSTRACT 
Objectives 
To determine whether iron deposition in deep brain nuclei assessed using 
high-pass filtered phase imaging play a role in motor disease severity  in 
Parkinson’s Disease (PD).  
Methods 
Seventy patients with mild-moderate PD and 20 age-gender-matched healthy 
volunteers (HV) underwent susceptibility-weighted imaging (SWI) on a 3T MRI 
scanner. Phase-shift (radians) in deep brain nuclei were derived from high-
pass filtered phase images and compared between groups. Analysis of 
clinical laterality and correlations with motor severity *(UPDRS-III) were 
performed. Radians were compared between HV and three PD sub-groups 
divided according to UPDRS-III scores using analysis of covariance, adjusting 
for age and regional area. 
Results 
PD patients had significantly (p<0.001) higher radians than HV bilaterally in 
the Putamen, Globus Pallidus and Substantia Nigra (SN). The SN 
contralateral to the most affected side showed higher radians (p<0.001) 
compared to the less affected side. SN radians positively correlated with 
UPDRS-III and bradykinesia-rigidity subscores, but not with tremor subscores. 
ANCOVA followed by post-hoc Bonferroni-adjusted pairwise comparisons 
revealed that SN radians were significantly greater in the PD subgroup with 
higher UPDRS-III scores as compared to both lowest UPDRS-III PD and HV 
groups (p<0.001).  
Conclusion 
Increased nigral iron accumulation in PD appears to be stratified according to 
disease motor severity and correlates with symptoms related to dopaminergic 
neurodegeneration. This semi-quantitative in vivo iron assessment could 
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prove useful for objective monitoring PD progression, especially in clinical 
trials concerning iron chelation therapies. 
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INTRODUCTION 
Iron plays an important role in PD neurodegeneration. Post-mortem and in 
vitro studies have demonstrated links between iron accumulation and the 
cardinal pathological features of Parkinson’s disease, the loss of dopamine 
neurons in the substantia nigra pars compacta (SNc) (1) and the presence of 
α-synuclein-rich Lewy bodies (2). Free ferrous iron (Fe2+) acts as a catalyst in 
a reaction with hydrogen peroxide (Fenton reaction), producing highly toxic 
reactive oxygen species (ROS) and ferric iron (Fe3+) that leads to oxidative 
stress-related damage to cellular components including proteins, lipids and 
DNA (3). To relieve potential toxicity, excess ferrous iron within deep brain 
nuclei is accumulated and transported into the core of apoferritin molecules 
where it is oxidized and safely stored in high concentrations in ferric state (4). 
Since ferritin (iron-containing apoferritin) is highly paramagnetic and indeed 
one of the only non-heme iron molecules present in sufficient quantity to 
cause local field inhomogeneities (4, 5), magnetic resonance imaging (MRI) 
can be used to measure ferritin-bound ferric iron in vivo. Given that the 
biosynthetic rate of apoferritin is modulated by the availability of free iron (6, 
7), changes in ferritin-related MR signal are reflective of alterations in iron 
load.  
In vivo iron quantification using MRI relaxometry (T2*, R2*) or Susceptibility-
Weighted Imaging (SWI) consistently demonstrates increased SN iron levels 
in patients with PD relative to healthy volunteers (8-18), while results 
pertaining to striatal regions such as caudate nucleus, putamen and globus 
pallidus appear highly heterogeneous (8-16). Several studies observe 
relationships between increased nigral iron accumulation, disease duration 
and motor severity (12-14, 18) though to our knowledge there are currently no 
cross-sectional studies that evaluate whether significant changes in iron 
accumulation exist between different stages of disease burden in 
mesencephalic or striatal nuclei. In addition, it remains unclear as to the effect 
of iron accumulation on differing motor symptoms, with the two studies to 
investigate tremor and akinetic/rigid predominance yielding conflicting results 
(16, 17).  
European Journal of Neurology 
Martin-Bastida et al 2016 
 
Consequently the goal of this study was to 1) evaluate differences in iron 
accumulation in deep brain nuclei between PD groups of varying motor 
severity and 2) to investigate the association between motor symptomatology 
and iron load. We use phase images obtained as part of an SWI protocol 
because they contain information on the tissue magnetic susceptibility 
distribution, a property shown to be influenced by ferritin and hemosiderin 
(breakdown product of ferritin) and which correlates with iron concentrations 
post-mortem (14, 19). Conventional relaxometry techniques are also affected 
by background field inhomogeneities such as tissue water content and air-
tissue interfaces, thus phase images represent a more direct means to 
estimate iron (4). This work demonstrates the value of iron quantification as 
an objective means by which patients can be monitored and stratified, 
particularly in the light of developing iron modifying therapies.  
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METHODS 
Subjects 
Seventy non-demented mild-moderate stage PD patients and twenty age-
gender-matched healthy volunteers (HV) were included in this study (see 
Table S1 for recruitment information). Diagnosis of PD was performed by 
movement disorder specialists according to the PDUK Brain Bank Criteria 
(20), excluding atypical parkinsonism, concomitant vascular load, history of 
cognitive impairment and  neurodegenerative disorders other than PD. 
Data were collected under the TransEuro and PaMIR studies, funded by FP7 
and Parkinson’s UK respectively and carried out in accordance with the 
Declaration of Helsinki, after approval from the National Research Ethics 
Service Committee. All participants gave written informed consent before 
participation.  
 
Motor assessment 
Motor symptomatology was measured using the Unified Parkinson’s Disease 
Rating Scale, part III (UPDRS-III). Patients were instructed to withdraw from 
medication 24 hours prior to assessment. Off-medication UPDRS-III scores 
were then subdivided into tremor (sum of items 15-18) and bradykinesia-
rigidity subscores (sum of items 2-9 and 14). Levodopa-equivalent daily dose 
(LEDD) was calculated.  
 
Susceptibility-Weighted Imaging  
Susceptibility-weighted images were acquired on a 3T Siemens Magnetom 
Trio system with 32-channel phased-array head coil running a T2-weighted 
3D gradient-echo sequence (SWI: TR=28ms, TE=20ms, Flip Angle=15°, 
bandwidth=120 Hz/Px, matrix size=294*320, FoV=230*230mm, GRAPPA 
acceleration factor=2). 72 slices of 1.9mm thickness and slice gap of 20% 
were obtained in an interleaved order parallel to the anterior-posterior 
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commissural line in the left-hand reference system. A small number of 
participants (4PD, 7HV) underwent a modified SWI protocol in which 88 slices 
of 0.9mm thickness with a 20% slice gap were acquired. Phase images were 
reconstructed automatically on the Siemens workstation (Syngo MR B17 
software, SWI version 1), which included application of a 64*64 high-pass 
filter to remove low spatial frequency effects.  
 
Regions of Interest Analysis 
Manual ROI delineation was performed by a trained investigator (AMB) on 
both PD and HV high-pass filtered phase images using SPIN (Signal 
Processing in Nuclear Magnetic Resonance; MRI institute, Detroit, Michigan). 
All study subjects were anonymised prior to delineation, thus blinding group 
and disease severity. ROIs were hand drawn on a single axial slice and 
included head of the caudate nucleus, putamen and globus pallidus (Figure 
1). The SN was delineated on the 3rd axial slice ventral to the most dorsal 
aspect of the red nucleus. For images acquired under the modified SWI 
protocol, the 5th axial slice ventral to the most dorsal aspect of the red nucleus 
was used (Figure S1). Independent samples t-tests showed no significant 
differences in SN radians between the two SWI protocols for either group 
(p>0.05) (Table S2). Subjects with microvascular lesions or physiological 
calcifications in the globus pallidus were not included in the analysis. 
Mean phase-shift values, number of voxels, standard deviations and regional 
areas were extracted for each ROI unilaterally before averaging to obtain 
bilateral data. Phase-shift values were converted to radians according to the 
formula provided for the Siemens left-handed system: Radians=(ϕ-
2048)π/2048 (21). 
<Figure 1> 
 
Statistical Analysis 
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All statistical analyses were performed using SPSS statistical software 
(version 22.0 SPSS Inc., Chicago, Illinois).  
Group demographics and bilateral radians for each region were compared 
between PD and HV using independent t-tests. ROIs showing a significant 
difference were considered for analyses of covariance (ANCOVA) in which 
PD patients, subdivided into 3 disease severity groups using UPDRS-III tertile 
calculations (Table 1) were compared to the HV group, adjusting for age and 
regional area and followed with post-hoc Bonferroni-adjusted pairwise 
comparisons. 
To assess hemispheric iron load differences in the PD group, radians for 
clinically most/least affected sides, as indicated by UPDRS-III laterality items, 
were compared for each region using independent t-tests.  
Pearson’s correlation coefficient was used to assess relationships between 
each ROI and measures of disease severity (disease duration, UPDRS-III 
total, tremor and bradykinesia/rigidity). Correlations were considered 
significant only if p<0.05 following Benjamini-Hochberg FDR adjustment. 
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RESULTS 
Participants 
Clinical and demographic data are summarized in Table 1. There were no 
significant differences in age (p=0.347) between PD and HV. Although the 
male:female ratio was higher in the PD group (p=0.039), no significant gender 
differences in iron accumulation were found. 
As expected, PD subgroups exhibited significant differences in motor severity, 
disease duration, LEDD and H&Y scores (Table 1). There were no significant 
differences between subgroups for age or gender.  
<Table 1> 
 
Phase-shift analysis 
Shapiro-Wilk's test revealed that putaminal and pallidal radians were not 
normally distributed (p<0.05). Square root transformations were therefore 
applied to the putamen and logarithmic transformation to globus pallidus. The 
PD group showed significantly higher radians in the putamen, globus pallidus 
and SN (p<0.001), as compared to HV (Figure 2). No significant difference 
was found in the caudate nucleus.  
<Figure 2> 
ANCOVA including HV and PD subgroups indicated main effects of motor 
severity in the putamen (F=6.346, p<0.001), globus pallidus (F=7.998, 
p<0.001) and SN (F=65.008, p <0.001) (Table 2). Post-hoc Bonferroni-
adjusted pairwise comparisons showed that radians in all three PD subgroups 
were significantly higher than HV in the globus pallidus (p=0.025, p<0.001 and 
p=0.001 respectively) and SN (p<0.001, p<0.001 and p<0.001 respectively) 
(Table 2). Putaminal radians were significantly higher in PD subgroups 1 and 
2 (p=0.006, p<0.001) as compared to HV. Pairwise comparisons between the 
PD subgroups revealed significance only in the SN, that is, PD group 1 
showed significantly lower radians as compared to PD groups 2 (p=0.049) 
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and 3 (p=0.001). Although PD group 3 showed the highest radians in the SN, 
no statistically significant difference was found when compared with PD group 
2 (p=0.236) (Figure 3). 
<Table 2> 
<Figure 3> 
 
Analysis of clinical laterality 
The SN contralateral to the clinically most affected side showed higher 
radians (p<0.001) compared to the least affected side. No other significant 
results were found. 
 
Correlations with disease duration and motor severity 
Pearson’s correlation analysis revealed significant positive correlations 
between SN radians and total UPDRS-III (r=0.420, p<0.001) and 
bradykinesia-rigidity subscores (r=0.407, p=0.001) but not with tremor 
(r=0.219, p=0.071) (Figure 4). Correlations remained significant after 
Benjamini-Hochberg FDR correction for multiple comparisons. 
Within the HV group, SN radians positively correlated with age (r=0.533, 
p=0.016).  
<Figure 4> 
 
Validation of phase-shift data 
To validate whether phase-shift data provide a quantitative measure of iron, 
Pearson’s correlations were conducted between deep brain grey matter nuclei 
radians from the healthy volunteer group and distribution of non-heme iron at 
autopsy, as reported by Hallgren and Sourander (1958) (22). A positive 
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correlation was found after exclusion of CN due to spatial discordance with 
regards to regional iron measurements (r=0.874, p=0.01) (Figure S2). 
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DISCUSSION 
This cross-sectional magnetic resonance imaging study evaluated regional 
iron deposition in deep brain nuclei, using high-pass filtered phase images to 
quantify average phase-shift (radians) in a large cohort of PD patients as well 
as age-matched healthy volunteers. 
Higher levels of iron, as measured using radians, were found in the SN of PD 
patients relative to the HV group. Further, when PD groups were subdivided 
according to UPDRS-III score, the SN showed a stratified distribution in which 
iron accumulation increased with motor severity. The SN is particularly 
vulnerable to abnormal increases in iron. Neuromelanin (NM), which under 
normal conditions acts as a neuroprotective iron chelator, is released into the 
extracellular space as a result of nigral cell death. Extracellular neuromelanin 
then releases ferric iron, which in turn promotes oxidative stress, microglial 
activation and further neuronal death (23). Indeed, increased nigral iron has 
been largely demonstrated in imaging studies using both SWI and 
relaxometry techniques (8-18). Recent longitudinal studies have also shown 
that changes in SN iron accumulation over time correlate with changes in 
motor severity (24, 25). Our design provides further evidence that this effect is 
not limited to increases within individuals but that significant changes can be 
seen between patients at different stages of disease. We note that although 
there was an increase in iron from moderate to high PD groups, this was not 
significant, suggesting that the rate of accumulation may decrease as the 
disease progresses. These findings cannot be explained by age differences, 
which is well-known to correlate with nigral iron levels (26) nor between-
patient nigral size, since both were added as covariates in our model. 
Increased iron deposition was also found in the putamen and globus pallidus, 
though no difference was found in the caudate nucleus. Results relating to 
striatal mineralisation have been highly variable, with several studies reporting 
increases (8, 11, 13, 15), reductions (9, 10) or normal levels (12, 14, 16) in 
PD. One possible explanation for this heterogeneity could be due to the 
presence of calcifications in the striatum, which may cause SWI and 
relaxometry techniques to underestimate iron levels. Recently however, Ulla 
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et al (24) demonstrated in an early PD cohort, that whilst there was a 
significant increase in R2* signal in the caudal putamen between baseline and 
three year follow-up as compared to healthy volunteers, the rostral putamen 
remained at normal levels. Thus, the heterogeneity of results within the 
literature may be attributable to a rostro-caudal gradient of mineralisation, 
which in turn may be dependent on disease duration. In addition, our data, 
though non-significant, show a trend for an initial increase of iron 
accumulation from low to moderate PD motor severity followed by a decrease 
from moderate to high motor severity in both the putamen and globus pallidus. 
Interestingly, this trend is in accordance with Ryvlin et al (9) who suggested 
that mineralization in these regions inversely correlate with disease duration 
when the duration of illness is above ten years. In contrast to the SN, it is 
clear that the mechanism behind striatal iron accumulation is not yet 
understood. Further longitudinal studies with patients followed-up to the point 
of moderate to high motor severity are required to more accurately 
characterise the trajectory of striatal mineralisation in PD.  
SN iron has previously been shown to strongly correlate with disease duration 
and motor severity (12-14, 18). Here, we add that this relationship may be 
driven by bradykinesia/rigidity symptomatology, since although a strong 
relationship was found between these measures no association with tremor 
was identified. Bradykinesia and rigidity symptoms result as a direct 
consequence of dopaminergic nigral neurodegeneration (27), which is 
associated with regional iron accumulation (1). In contrast, tremor does not 
only reflect dopaminergic nigro-striatal degeneration but may also be 
associated with serotoninergic and noradrenergic pathology (28). Indeed, we 
recently found that dopaminergic presynaptic terminal availability as well as 
storage capacity in the putamen and caudate nucleus were negatively 
associated with bradykinesia and rigidity scores, but not with tremor (Li and 
Lao-Kaim et al, unpublished observations). Bunzeck et al found a significant 
association between striatal iron accumulation and tremor symptomatology, 
suggesting that putaminal iron may be used as a predictor for tremor 
dominance in early PD (17). However, their measures were collected in the 
“on” medication state whilst our assessments were conducted in the “off” 
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medication state in order to avoid the confounding effect of variable clinical 
benefit with respect to tremor. Thus our data suggest that iron levels in the SN 
may be a feasible biomarker of bradykinesia and rigidity progression in PD. 
The use of high-pass filtered phase imaging may be of therapeutic interest. 
Iron chelators that cross the blood-brain barrier, such as Deferiprone, used 
mainly for peripheral haematological disorders, show a disease-modifying 
effect in animal models of PD (29). So far, two randomized clinical trials with 
this drug have been conducted in PD patients, showing small reductions in 
motor severity after 6-12 months of treatment without major medication-
related side effects (30) (Martin-Bastida et al, unpublished observations). 
However, MR relaxometry data were not consistent between these studies, 
detecting different degrees of regional chelation. Conventional relaxometry 
techniques (T2* and R2*) estimate iron load in vivo using gradient-echo (GE) 
sequences that are sensitive to variations in transverse relaxation times/rates 
between different tissues and which are affected by both macroscopic and 
microscopic magnetic field inhomogeneities (31). However, images produced 
using these methods can be affected by changes in tissue water content and 
other background field inhomogeneities such as those resulting from air-tissue 
interfaces (4, 31). In contrast, SWI sequences, while also utilising T2* 
weighting involve the collection of both magnitude and phase images using a 
3D velocity-compensated GE sequence. In particular, phase images contain 
information on the tissue magnetic susceptibility distribution. Since 
paramagnetic molecules such as ferritin and hemosiderin influence the local 
magnetic field and therefore the phase of the MR signal (31), phase offers 
greater specificity to quantifying brain iron load. Phase images are also more 
robust to the presence of noise (32) and the removal of low spatial frequency 
artefacts that could otherwise obscure intertissue phase differences (using a 
high-pass filter) (33) further improve its sensitivity to detecting abnormal iron 
levels. Thus, high-pass filtered phase images are a good alternative for 
monitoring the effects of iron chelators longitudinally. 
There are some limitations with our study. First, we analyzed the slice with the 
highest iron-content in order to avoid background artifacts. Although no ROI 
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size differences were found between PD and HV, this method may not reflect 
the iron content of the entirety of each nucleus.  
Second, although it is well documented that the pars compacta (SNc) and 
pars reticulata (SNr) present differential levels of mineralization, we analyzed 
the SN without further segmentation. Post-mortem studies including those 
immunostaining for calbindin D28K (34) have provided valuable information on 
the definition of nigral compartments based on dopamine cell-independent 
anatomical landmarks. However, translation to MRI segmentation is not 
straightforward due to technical considerations (acquisition volume, slice 
orientation and thickness) and imperfect correspondence between 
anatomically defined nigral distribution and that observed on T2-weighted 
images (35, 36). Nevertheless, attempts have been made to manually 
separate the nigra albeit with significant methodological variation (12, 24), 
highlighting disagreement on best localization procedures. More sophisticated 
techniques have recently been developed involving multimodal analysis of 
both SWI and NM-sensitive T1-weighted MRI (magnetization transfer) with 
which reduced NM pigmentation has been demonstrated in the SNc in PD 
with very high sensitivity and specificity (37, 38). However, the authors note a 
spatial overlap of 12.6±4.6% between the two SN volumes further reflecting 
the difficulty of accurately segmenting the SN (39). Given the inability of 
phase images to resolve intra-nigral boundaries, we opted to delineate the SN 
as a whole in order to maintain accuracy of our measurements, though we 
acknowledge that this was at the cost of specificity and conclusiveness with 
regards to the level of mineralization for each sub-region and their relationship 
to PD pathology. Higher MR field strength and the use of quantitative 
susceptibility mapping (40) which can further reduce phase image artefacts 
may provide greater spatial validity with respect to iron and improve the 
accuracy with which nigral compartments can be interrogated.   
In summary, our results demonstrate that the degree of iron accumulation in 
PD is stratified according to disease severity in the SN but not in striatal sub-
regions and that nigral iron is associated with the severity of bradykinesia and 
rigidity rather than tremor. Phase imaging techniques could be an important 
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tool for monitoring clinical progression and establishing the efficacy and 
neuroprotective effects of iron chelation therapies in PD patients of variable 
clinical phenotype.  
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FIGURE LEGENDS 
Figure 1: Regions of interest delineated on axial slices of high-pass filtered 
phase images. A: Head of caudate nucleus (1), Putamen (2), Globus pallidus 
(3). B: Substantia nigra (4). C: Sagittal 3D MPRAGE T1-weighted image 
indicating level of ROI delineation. 
Figure 2:  Comparison of radians between PD (grey bars) and HV (white 
bars) CN= Caudate Nucleus; Put= Putamen; GP=Globus Pallidus; SN= 
Substantia Nigra. ***p<0.001, **p<0.01, *p<0.05. 
Figure 3: Box and whisker plot displaying ANCOVA results for the SN.PD 
group 1 (UPDRS III=19.3 ± 3.11); PD group 2 (UPDRS III=29.27 + 3.13); PD 
group 3 = 44.60 ± 6.42). Ad -hoc Bonferroni-adjusted pairwise comparison 
significance levels indicated as follows: ***p<0.001, **p<0.01, *p<0.05. 
Figure 4: Pearson’s correlations of SN radians with UPDRS-III, bradykinesia-
rigidity and tremor scores. 
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SUPPLEMENTARY INFORMATION LEGENDS 
Figure S1: Axial slices of two different subjects comparing SN delineation 
between the main (slice thickness =1.9, no. of slices =72) and modified (slice 
thickness =0.9, no. of slices =88) SWI protocols. For the main SWI protocol, 
delineation was conducted on the 3rd axial slice ventral to the most dorsal 
aspect of the red nucleus (left). For the modified SWI protocol, delineation 
was conducted on the 5th axial slice ventral to the most dorsal aspect of the 
red nucleus (right). 
Figure S2: Pearson’s correlations between phase-shift radians of deep brain 
grey matter nuclei from the healthy volunteer group (n=20) with the 
distribution of non-heme iron at autopsy (mg iron/100 gr fresh tissue), as 
reported by Hallgren and Sourander (1958). In addition to the putamen (Put), 
globus pallidus (GP), Substantia Nigra (SN) and head of the caudate nucleus 
(CN), radians were also derived from the thalamus (Tha), red nucleus (RN) 
and dentate nucleus (DN). After exclusion of CN as an outlier, we found a 
positive correlation between radians and non-heme iron (mg/100 g fresh 
weight) (r=0.874, p=0.01) (left). We hypothesised that the appearance of the 
CN as an outlier was related to a regional discordance; while Hallgren and 
Sourander (1958) reported non-heme values for the whole caudate, in this 
manuscript we originally reported values specifically for the caudate head 
only, which we observed had the highest iron values within the whole nucleus. 
We therefore also analysed the body of the caudate (CNb) and re-ran the 
correlation, substituting CN for CNb. Again we found a significant correlation 
between radians and non-heme iron (mg/100 g fresh weight) (r=0.624, 
p=0.034) (right). 
Table S1: Study volunteer recruitment from TransEuro and PaMIR studies. 
PD = Parkinson’s disease volunteers, HV = healthy volunteers. 
Table S2: Independent samples t-tests comparing SN radians between the 
main SWI protocol 1 (slice thickness =1.9, no. of slices =72) and the modified 
SWI protocol 2 (slice thickness =0.9, no. of slices =88) for HV and PD groups. 
Values represent the mean±SD. 
